Literature DB >> 21348766

Implementation and enforcement of ventilator-associated pneumonia prevention strategies in trauma patients.

Jessica Heimes1, Carla Braxton, Niaman Nazir, Nina Shik, Elizabeth Carlton, Todd Lansford, John Alley, Jessica McDonnell, Tracy Rogers, Michael Moncure.   

Abstract

BACKGROUND: We hypothesized that strict enforcement of ventilator-associated pneumonia (VAP) prevention (VAPP) strategies would decrease the incidence of VAP and improve patient outcomes.
METHODS: This retrospective study examined 696 consecutive ventilated patients in a Level One trauma center. Three study groups were compared: Pre-VAPP, VAPP implementation, and VAPP enforcement. Ventilator days were compared with occurrences of VAP, defined by the U.S. Centers for Disease Control and Prevention National Nosocomial Infection Surveillance criteria. Patients with and without VAP were compared to evaluate the effect of VAP on patient outcome. Fisher exact, Kruskal-Wallis, and chi-square analyses were used, and p < 0.05 was considered significant.
RESULTS: During the pre-VAPP protocol period, 5.2 cases of VAP occurred per 1,000 days of ventilator support. The number of cases of VAP decreased to 2.4/1,000 days (p = 0.172) and 1.2/1,000 days (p = 0.085) in the implementation and enforcement periods, respectively. However, when including all trauma patients, regardless of head Abbreviated Injury Score (AIS) score, the difference in the rate of VAP was statistically significant in the enforcement period, but not in the implementation period, compared with the pre-VAPP period (p = 0.014 and 0.062, respectively). A significant decrease was seen in the mortality rate (p = 0.024), total hospital days (p = 0.007), intensive care unit days (p = 0.002), ventilator days (p = 0.002), and hospital charges (p = 0.03) in patients without VAP compared with patients having VAP.
CONCLUSIONS: There was a statistically significant decrease in the occurrence of VAP with strict enforcement of a VAPP protocol, regardless of head AIS score. Although the difference in patients with a head AIS score <3 was not statistically significant, it was clinically meaningful, decreasing the already-low rate of VAP by half. Strict enforcement of VAPP protocols may be cost efficient for hospitals and prevent decreased reimbursement under the Medicare pay-for-performance strategies.

Entities:  

Mesh:

Year:  2011        PMID: 21348766     DOI: 10.1089/sur.2009.028

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  5 in total

1.  Hospital-acquired pneumonia is an independent predictor of poor global outcome in severe traumatic brain injury up to 5 years after discharge.

Authors:  Matthew Ryan Kesinger; Raj G Kumar; Amy K Wagner; Juan Carlos Puyana; Andrew P Peitzman; Timothy R Billiar; Jason L Sperry
Journal:  J Trauma Acute Care Surg       Date:  2015-02       Impact factor: 3.313

Review 2.  A systematic approach for developing a ventilator-associated pneumonia prevention bundle.

Authors:  Kathleen Speck; Nishi Rawat; Noah C Weiner; Haddis G Tujuba; Donna Farley; Sean Berenholtz
Journal:  Am J Infect Control       Date:  2016-02-10       Impact factor: 2.918

Review 3.  Healthcare-Associated Infections in the Neurocritical Care Unit.

Authors:  Katharina M Busl
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-27       Impact factor: 5.081

Review 4.  Pneumonia in Nervous System Injuries: An Analytic Review of Literature and Recommendations.

Authors:  Zohreh Erfani; Hesan Jelodari Mamaghani; Jeremy Aaron Rawling; Alireza Eajazi; Douglas Deever; Seyyedmohammadsadeq Mirmoeeni; Amirhossein Azari Jafari; Ali Seifi
Journal:  Cureus       Date:  2022-06-02

5.  Incidence of Device Associated-Healthcare Associated Infections from a Neurosurgical Intensive Care Unit of a Tertiary Care Center: A Retrospective Analysis.

Authors:  Gokuldas Menon; Avanthi Subramanian; Poornima Baby; Nimesh Daniel; R Radhika; Mathew George; Sajesh Menon
Journal:  Anesth Essays Res       Date:  2021-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.